BioSpace News Archive

Anyong Biotechnology, the world-class aquatic food processing company based in Taiwan, is now the first company in the region to employ Cells Alive System technology from Japan.

23andMe Holding Co., a leading consumer genetics and research company, appointed Daniel Chu as Chief Product Officer.

Cingulate Inc. announced findings from its formulation study for CTx-2103, the Company’s asset for the management of anxiety-related disorders.

GENFIT announced it has entered into an exclusivity agreement with a view to acquire all the share capital and voting rights of Versantis, a private Swiss-based clinical stage biotechnology company focused on addressing the growing unmet medical needs in liver diseases.

AbbVie announced the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending the approval of risankizumab for the treatment of adults with moderately to severely active Crohn’s disease who have had inadequate response, lost response or were intolerant to conventional or biologic therapy.

Theravance Biopharma, Inc. announced that its Board of Directors has authorized a $250 million capital return program consisting of the following three elements.

Sage Therapeutics, Inc. and Biogen Inc. announced new analyses from across the development program for zuranolone, an investigational, oral, once-daily, 14-day treatment in clinical development for adult patients with major depressive disorder and postpartum depression.

Bio-Techne Corporation (NASDAQ: TECH) today issued its 2022 Corporate Sustainability Report (CSR).

HistoSonics announced today the publication of results from their prospective Phase I clinical trial, named the THERESA Trial, conducted in Barcelona, Spain.

Virios Therapeutics, Inc. today announced topline results from its FORTRESS (Fibromyalgia Outcome Research Trial Evaluating Synergistic Suppression of Herpes Simplex Virus-1 (“HSV-1”)) study of oral IMC-1 for the treatment of FM.